MIA's Tim Beck interviews critical psychologist Thomas Teo on how theory and research can do justice to the people it means to describe and explain.
Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.
The healing power of communal singing is at the heart of two organizations in England and Ireland: Sing Your Heart Out and 49 North Street.
The Ministry of Health in Norway has ordered its four regional health authorities to offer medicine-free treatment in psychiatric hospitals. A six-bed ward in Tromso, which is in the far north of Norway, is now providing such care.
That is the truth about withdrawal syndrome: It’s like a 50-50 chance that you’re going to have a problem. If you’re in the unlucky half, you’re gonna be really unlucky.
Every year suicide hotline centers covertly trace tens of thousands of confidential calls, and police come to homes, schools, and workplaces to forcibly take callers to psychiatric hospitals.
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
The American Psychiatric Association and its former president, Jeffrey Lieberman, have used the Goldwater Rule to try to silence Yale psychiatrist Bandy Lee and colleagues who warned, in a collection of essays, about why President Trump is "dangerous." Why would a guild choose to do this?
MIA's Emaline Friedman interviews legal scholar Piers Gooding on his work on disability rights and digital mental health technologies.
In a MIA survey of people who had been patients in mental hospitals, nearly 500 respondents told of an experience that was often traumatic, and frequently characterized by a violation of their legal rights, forced treatment with drugs, and physical or sexual abuse. Only 17% said they were “satisfied” with the “quality of the psychiatric treatment” they received.
Peer-Support Groups Were Right, Guidelines Were Wrong: Dr. Mark Horowitz on Tapering Off Antidepressants
In an interview with MIA, Dr. Horowitz discusses his recent article on why tapering off antidepressants can take months or even years.
MIA’s Ayurdhi Dhar interviews Sunil Bhatia about decolonizing psychology, confronting the field’s racist past, colonial foundations, and neoliberal present.
MIA’s Samantha Lilly interviews critical youth suicidologist Jennifer White about what suicide prevention could look like outside of the medical model.
Ayurdhi Dhar interviews Tanya Luhrmann about cultural differences in voice-hearing, diagnosis and damaged identities, and conflicts in psychiatry.
After a meta-analysis of RCTs of antidepressants was published in Lancet, psychiatry stated that it proved that "antidepressants" work. However, effectiveness studies of real-world patients reveal the opposite: the medications increase the likelihood that patients will become chronically depressed, and disabled by the disorder.
Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.
At the Hurdalsjøen Recovery Center in Norway, patients with a long history of psychiatric hospitalizations are tapering from their medications and, in a therapeutic environment that emphasizes a good diet, exercise, and asking patients "what do they want in life," are leaving their old lives as chronic patients behind.
The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.
The ACE study tells of how adverse childhood experiences increase the risk of psychological and physical problems in adulthood. When will we start incorporating these findings into public health policy and medical care?
The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.
During the past twenty years, the American Foundation for Suicide Prevention and American psychiatry have adopted a "medicalized" approach to preventing suicide, claiming that antidepressants are protective against suicide. Yet, the suicide rate in the United States has increased 30% since 2000, a time of rising usage of antidepressants. A review of studies of the effects of mental health treatment and antidepressants on suicide reveals why this medicalized approach has not only failed, but pushed suicide rates higher.
The New Yorker's story on Laura Delano and psychiatric drug withdrawal is a glass-half-full story: It addresses a problem in psychiatry and yet hides the deeper story to be told. A story of how her recovery resulted from seeing herself within a counter-narrative that tells of the harm that psychiatry can do.
In Israel, there is a budding Soteria movement that foretells of a possible paradigm shift in care. The thought is that such care may become a first-line treatment for newly psychotic patients.
MIA's Madison Natarajan interviews Natalie Campo about integrative psychiatry and holistic approaches to drug tapering and withdrawal.
After 18 years, the full story of the scientific corruption in a study of paroxetine for bipolar disorder, and the psychiatrist who blew the whistle.